Your browser doesn't support javascript.
loading
Opportunities and Challenges of RNA Interference Therapeutics in Oncology / 中国肺癌杂志
Chinese Journal of Lung Cancer ; (12): 482-486, 2022.
Article in Chinese | WPRIM | ID: wpr-939735
ABSTRACT
As the discovery of RNA interference (RNAi) and the gradual conquering of a series of technical issues, a few of RNAi therapeutics have been approved in the non-tumor field abroad. With the advantages of high specificity, long duration of efficacy, and high success rate of development, RNAi therapeutics have become the emerging field globally. There are no RNAi therapeutics approved in oncology so far, and people are hoping a breakthrough in the field. In the present article, the characteristics and potential anti-tumor mechanism of RNAi therapeutics, difficulties in delivery system and progress in oncology are described, and the potential reasons why their success in non-tumor field is difficult to be simply replicated in tumor field are analyzed, providing reference for research and clinical transformation of RNAi therapeutics in oncology.
.
Subject(s)

Full text: Available Index: WPRIM (Western Pacific) Main subject: RNA, Small Interfering / RNA Interference / Lung Neoplasms Limits: Humans Language: Chinese Journal: Chinese Journal of Lung Cancer Year: 2022 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Main subject: RNA, Small Interfering / RNA Interference / Lung Neoplasms Limits: Humans Language: Chinese Journal: Chinese Journal of Lung Cancer Year: 2022 Type: Article